
The acquisition brings Gallant’s experimental stem cell treatments for chronic gingivostomatitis and osteoarthritis in dogs and cats into Dechra’s portfolio.
Taking the BizQuiz? This is question 3 from "Are you an underearner?"
3) Discounts and free care are...

